Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Dementia with Lewy bodies (DLB) is characterized clinically by fluctuating cognitive impairment, visual hallucinations, and parkinsonism.1 It is the second most common neurodegenerative disease that causes dementia after AD. The pathologic hallmark of the disease is the presence of Lewy bodies in the cerebral cortex as well as in the brainstem.1 In most cases, numerous senile plaques are also observed in the cerebral cortex, similar to those in the AD brain; neocortical neurofibrillary tangles (NFTs) are rare or absent.2,3 In AD, levels of CSF amyloid β42 (Aβ42) are decreased and levels of CSF tau are increased.4 CSF Aβ42 and tau are thought to be linked with plaques and tangles in the AD brain. Thus, we hypothesized that levels of CSF Aβ42 would be decreased and levels of CSF tau would be normal in DLB. To test this hypothesis we measured levels of CSF Aβ42 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H., Morikawa, Y.-I., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., Machida, N., Lee, V. M.-Y., Trojanowski, J. Q., & Sasaki, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6908 · Cited by 159
Cited by
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Dubois, B., Duda, J. E., Feldman, H., et al. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00619-7 · Cited by 618
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Metadata
- Authors
- Kanemaru, K., Kameda, N., & Yamanouchi, H.
- Venue
- Neurology
- Published
- 2000-05-09
- Volume
- 54
- Issue
- 9
- Pages
- 1875-1876
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030416707
- Cited by
- 157
- References
- 3
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. https://app.cochat.ai/papers/10.1212/wnl.54.9.1875
- The paper
- Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000). Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology. https://doi.org/10.1212/wnl.54.9.1875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.